Early Intervention in Acute Renal Failure
A multi-site randomised phase IV study to evaluate the effectiveness of intravenous erythropoietin in preventing intensive care unit patients with acute kidney injury from developing acute renal failure.
The Health Research Council of New Zealand
130 participants
Jan 23, 2006
Interventional
Conditions
Summary
Patients admitted to a general intensive care unit and high risk post cardiothoracic surgery patients will be screened for renal injury using urinary biomarkers and randomised within 6 hours of admission to two doses of placebo or erythropoietin at 24 hour intervals. Subjects, investigators and treating clinicians will be blinded to treatment throughout the study.
Eligibility
Inclusion Criteria1
- Gamma Glutamyl Transpeptidase X Alkaline Phosphatase index of >46.3 u/mmol. 2. Likely survival >72 hours. 3. Consent obtained.
Exclusion Criteria1
- Active cytotoxic chemotherapy in progress2. Pre existing renal disease (serum creatinine >0.345 mmol/L)3. presence of rhabdomyolysis and/or myoglobinuria4. Already enrolled in another interventional study or previously enrolled in this study5. Increase of plasma creatinine of > 43 µmol/L over the previous 24 hours.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous Erythropoietin in 2 doses at 0 and 24 hours after the detection of a raised urinary acute kidney injury index
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000058572